Dario Amodei responded to Nathan Calvin’s criticism of Anthropic’s actions. He listed costly pro-safety moves including SB 53 support, strong bio safeguards, delayed Mythos release, and export control advocacy. He defended internal compute spending and RSP changes as part of a race-to-the-top strategy. He acknowledged some mistakes but argued Anthropic’s overall record is strong. He cited a 5% stock contribution to a public benefit fund as a recent example. He said several criticized items were ordinary business decisions. He framed Anthropic’s approach as raising industry safety standards while competing at the frontier.